Oligonucleotide, and therapeutic agent for dyslipidemia containing oligonucleotide as active ingredient
An object of the present invention is to provide an oligonucleotide useful as a therapeutic agent for dyslipidemia that has excellent binding affinity to the PCSK9 gene as well as stability and safety. The oligonucleotide of the present invention contains a sugar-modified nucleoside, the sugar-modified nucleoside has a bridging structure between 4′-position and 2′-position, and the oligonucleotide can bind to the human PCSK9 gene. Also, the present invention provides a therapeutic agent for dyslipidemia containing the oligonucleotide as an active ingredient, and the therapeutic agent preferably contains a bioabsorbable material as a carrier. The bioabsorbable material is preferably atelocollagen or peptide gel.
1. An oligonucleotide comprising a sugar-modified nucleoside,
the sugar-modified nucleoside having a bridging structure between 4′-position and 2′-position, and
the oligonucleotide being capable of binding to human PCSK9 gene,
wherein the bridging structure is represented by —CO—NR 1 —, —CH 2 —CO—NR 1 —, —(CH 2 ) 2 —CO—NR 1 —, —CO—NR 1 —X—, or —CH 2 —CO—NR 1 —X—, wherein
R 1 is a hydrogen atom;
a C 1-7 alkyl group that may form a branch or ring;
a C 2-7 alkenyl group that may form a branch or ring;
a C 3-12 aryl group that may have any one or more substituents selected from an α group consisting of a hydroxyl group, C 1-6 linear alkyl group, C 1-6 linear alkoxy group, mercapto group, C 1-6 linear alkylthio group, amino group, C 1-6 linear alkylamino group, and halogen atom, and that may contain a hetero atom; or
an aralkyl group having a C 3-12 aryl portion that may have any one or more substituents selected from the α group and that may contain a hetero atom; and
X is an oxygen atom, sulfur atom, amino group, or methylene group.
2. The oligonucleotide according to claim 1 , wherein the human PCSK9 gene is a DNA or RNA composed of a base sequence containing any of the following base sequences: base sequence of SEQ ID NO. 3; base sequence of SEQ ID NO. 4; base sequence of SEQ ID NO. 5; base sequence of SEQ ID NO. 6; base sequence of SEQ ID NO. 7; base sequence of SEQ ID NO. 8; base sequence of SEQ ID NO. 9; base sequence of SEQ ID NO. 10; base sequence of SEQ ID NO. 11; base sequence of SEQ ID NO. 12; base sequence of SEQ ID NO. 13; base sequence of SEQ ID NO. 14; base sequence of SEQ ID NO. 15; base sequence of SEQ ID NO. 16; base sequence of SEQ ID NO. 17; base sequence of SEQ ID NO. 18; or base sequences complementary to these.
3. The oligonucleotide according to claim 1 , wherein the oligonucleotide has a base sequence length of 10 to 25 bases.
4. The oligonucleotide according to claim 1 , wherein at least one selected from the group consisting of an intercalator, reporter molecule, polyamine, polyamide, polyethylene glycol, thioether, polyether, cholesterol, thiocholesterol, cholic acid portion, folic acid, lipid, phospholipid, biotin, phenazine, phenanthridine, anthraquinone, adamantane, acridine, fluorescein, rhodamine, coumarin, and pigment is bound to a 5′-end or 3′-end of the oligonucleotide.
5. A therapeutic agent for dyslipidemia, comprising an oligonucleotide of claim 1 as an active ingredient.
6. The therapeutic agent according to claim 5 , which is a sustained-release preparation comprising a bioabsorbable material as a carrier.
7. The therapeutic agent according to claim 6 , wherein the bioabsorbable material is atelocollagen or peptide gel.
8. A therapeutic agent for dyslipidemia, comprising an oligonucleotide of claim 2 as an active ingredient.
9. The therapeutic agent according to claim 8 , which is a sustained-release preparation comprising a bioabsorbable material as a carrier.
10. The therapeutic agent according to claim 9 , wherein the bioabsorbable material is atelocollagen or peptide gel.